Successful management with bisphosphonate treatment in a child with tuberculosis-associated hypercalcemia

被引:0
作者
Kilinc, Suna [1 ]
Bostan, Ozlem [2 ]
Erol, Meltem [2 ]
Erturk, Saide [3 ]
Dilek, Damla [2 ]
Yigit, Ozgul [2 ]
机构
[1] Istanbul Bagcilar Training & Res Hosp, Dept Pediat Endocrinol, Istanbul, Turkey
[2] Istanbul Bagcilar Training & Res Hosp, Dept Pediat, Istanbul, Turkey
[3] Istanbul Esenler Obstet & Pediat Hosp, Dept Pediat, Istanbul, Turkey
关键词
Bisphosphonates; hypercalcemia; miliary tuberculosis; pamidronate-disodium; VITAMIN; CALCIUM;
D O I
10.14744/nci.2019.14890
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypercalcemia is a common metabolic abnormality in children and generally occurs due to hyperparathyroidism, vitamin D toxicity, some genetic disorders and malignant diseases. Granulomatous diseases are a rare cause of hypercalcemia in children, which are usually mild and asymptomatic. Severe hypercalcemia in granulomatous diseases has also been reported in the literature. Here, we report a child presenting with severe hypercalcemia secondary to miliary tuberculosis with successful management with bisphosphonate treatment. Increased 1,25(OH)2D3 synthesis by activated macrophages in the granuloma tissue is the major mechanism of hypercalcemia in tuberculosis.
引用
收藏
页码:411 / 414
页数:4
相关论文
共 50 条
  • [41] Diagnosis and management of hypercalcemia associated with silicone-induced granuloma
    Hamadeh, Majdi
    Fares, Jawad
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2018, 64 (07): : 575 - 576
  • [42] Bisphosphonate Use Is Not Associated With Tuberculosis Risk Among Patients With Osteoporosis: A Nationwide Cohort Study
    Chen, Jin-Hua
    Lee, Chih-Hsin
    Lee, Meng-Rui
    Huang, Pei-Yu
    Yen, Tzu-Hsin
    Lee, Ming-Chia
    Tsai, Ching-Wen
    Wang, Jann-Yuan
    Lee, Jen-Ai
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (11) : 1412 - 1418
  • [43] LEVELS OF PARATHYROID HORMONE-RELATED PROTEIN (PTHRP) IN HYPERCALCEMIA OF MALIGNANCY ARE NOT LOWERED BY TREATMENT WITH THE BISPHOSPHONATE BM 21.0955
    BLIND, E
    RAUE, F
    MEINEL, T
    WUSTER, C
    ZIEGLER, R
    HORMONE AND METABOLIC RESEARCH, 1993, 25 (01) : 40 - 44
  • [44] TREATMENT OF TUMOR-INDUCED HYPERCALCEMIA WITH THE BISPHOSPHONATE PAMIDRONATE - DOSE-RESPONSE RELATIONSHIP AND INFLUENCE OF TUMOR TYPE
    BODY, JJ
    DUMON, JC
    ANNALS OF ONCOLOGY, 1994, 5 (04) : 359 - 363
  • [45] Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift
    O'Callaghan, Sondra
    Yau, Hanford
    ENDOCRINE CONNECTIONS, 2021, 10 (01): : R13 - R24
  • [46] Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment
    Kwon, Tae-Geon
    Lee, Chung-O
    Park, Jin-Woo
    Choi, So-Young
    Rijal, Girdhari
    Shin, Hong-In
    CLINICAL ORAL IMPLANTS RESEARCH, 2014, 25 (05) : 632 - 640
  • [47] Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies
    N. Napoli
    D. Novack
    R. Armamento-Villareal
    Osteoporosis International, 2010, 21 : 705 - 708
  • [48] Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies
    Napoli, N.
    Novack, D.
    Armamento-Villareal, R.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (04) : 705 - 708
  • [49] Teriparatide’s role in the management of bisphosphonate-associated osteonecrosis of the jaw
    G. Subramanian
    S. Y. P. Quek
    Osteoporosis International, 2012, 23 : 2727 - 2728
  • [50] Successful treatment of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) patients with sitafloxacin: New strategies for the treatment of BRONJ
    Ikeda, Tetsuya
    Kuraguchi, Jun
    Kogashiwa, Yasunao
    Yokoi, Hidenori
    Satomi, Takafumi
    Kohno, Naoyuki
    BONE, 2015, 73 : 217 - 222